Skip to main content

Table 2 Different published studies used radiotherapy for PPTID

From: Are we over treating Pineal Parenchymal tumour with intermediate differentiation? Assessing the role of localised radiation therapy and literature review

Authors Total Number of patients in the study Total number of patients with radiotherapy Number of patients with Craniospinal radiotherapy Dose Stereotactic Chemotherapy Outcome
Schild et al. (1993) 4 4 Not clear 45–64.8 Gy Not clear Not clear No specific data
Fauchon et al. (2000) 26 patients were classified as Grade 2 and Grade 3 not PPID 14 12 Neuroaxis
Dose average 31 Gy (range 10–38 Gy)
Yes Yes 6 patients
Various regime
5 years survival 74 % and 39 % for Grade 2 and 3 respectively
Lutterbach et al. (2002) 37 specimens were retrospectively analysed to classify them as PPTIDs Not clear Not clear Range 20–75 Gy
Median 54 Gy
Yes Yes
Cis/Vin, Cis/Eto, Cap/Ifo,
VIP16/Cis, Vip16/D/F, MTX it, LO/CIS/VI
Median overall survival 165 months
Stoiber et al. (2010) 1 1 0 54 Gy/30 f L No No Time to progression 84 months
Tsubasa et al. (2014) 5 5 2 L 54 Gy,
CSI 36 Gy
WVI 18
No Yes 4 patients
VNCI
Medial overall survival 94.1 months
Ito et al. (2014) 6 6 4 22 Gy/10 f L
54.4 Gy/28 f WB + L+WS
50 Gy/25 f
EL+L
Yes Yes 3 patients
ACNU,VDS,VCR,ICE
Median event free survival 39 months
  1. L local, EL extended local, WB whole brain, WS whole spine, WVI whole ventricular irradiation, VNCI vincristine, nimustine, carboplatin, interferon, CSI craniospinal irradiation, ACNU, 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride, VDS vindesine, VCR vincristine; ICE ifosfamide + cis-platinum + etoposide, Cis cisplatinum, Vi vincristine, VP16 etoposide, MTX methotrexate, l0 Lomustiene